The Discounted Cash Flow (DCF) valuation of Kymera Therapeutics Inc (KYMR) is (158.39) USD. With the latest stock price at 62.89 USD, the upside of Kymera Therapeutics Inc based on DCF is -351.9%.
Based on the latest price of 62.89 USD and our DCF valuation, Kymera Therapeutics Inc (KYMR) is a sell. selling KYMR stocks now will result in a potential gain of 351.9%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.6% - 8.8% | 7.7% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (357.92) - (102.24) | (158.39) |
| Upside | -669.1% - -262.6% | -351.9% |